$heff's $tation of $tocks & $olid DD

[kei]

MRNS - a lots going on with this tiny biotech this year

<ash's dd> Near-term Clinical Value Catalysts ·

Initiate Phase 2 study in women with postpartum depression (PPD) in 1H 2017 ·
Initiate Phase 2 study in patients with refractory status epilepticus (RSE) in 1H 2017 ·
Report top-line data from patients with orphan, genetic disorders in mid-2017 ·
Report data from PPD patients in 2H 2017 ·
Report data from RSE patients in 2H 2017
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11773218

Third Quarter Financial Update At September 30, 2016, the Company had cash, cash equivalents and investments of $37.1 million, compared to $57.7 million at December 31, 2015. The Company believes that its cash, cash equivalents and investments, as of September 30, 2016, are adequate to fund operations into the second half of 2018.

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of November 7, 2016 was: 19,705,495.